Free Trial

UCB SA (OTCMKTS:UCBJY) Short Interest Up 859.4% in April

UCB logo with Medical background

UCB SA (OTCMKTS:UCBJY - Get Free Report) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 30,700 shares, a growth of 859.4% from the March 31st total of 3,200 shares. Based on an average daily volume of 133,100 shares, the short-interest ratio is currently 0.2 days. Currently, 0.0% of the shares of the stock are sold short.

UCB Trading Up 0.1 %

OTCMKTS:UCBJY traded up $0.10 on Thursday, reaching $91.91. The stock had a trading volume of 25,896 shares, compared to its average volume of 43,632. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. UCB has a 1-year low of $63.58 and a 1-year high of $106.60. The stock has a fifty day moving average price of $89.64 and a 200-day moving average price of $94.13.

UCB Increases Dividend

The firm also recently disclosed a dividend, which will be paid on Wednesday, May 14th. Shareholders of record on Tuesday, April 29th will be paid a $0.4838 dividend. The ex-dividend date is Monday, April 28th. This represents a yield of 0.62%. This is a positive change from UCB's previous dividend of $0.46.

About UCB

(Get Free Report)

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

Featured Articles

Should You Invest $1,000 in UCB Right Now?

Before you consider UCB, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UCB wasn't on the list.

While UCB currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

This $13 Trillion Energy Breakthrough Will Make Millionaires
Magnificent 7 Stocks Shift Toward Stability and Selective Growth
4 Biotech Stocks on the Verge of Massive Breakthroughs

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines